Peripheral Artery Disease (PAD) is a common condition that is often underdiagnosed and undertreated1,2
That’s why Abbott remains committed to raising awareness about PAD among physicians and patients to receive a timely diagnosis followed by appropriate treatment.
Abbott's CLEAR Program was developed specifically for physicians to:
- Enhance awareness and understanding of PAD
- Facilitate early referral of patients
- Boost networking and collaboration between referring HCPs and vascular specialists
- Provide easy-to-use tools to streamline referral pathway efficiency
- Help prevent PAD progression to chronic limb-threatening ischemia (CLTI), save patients' limbs and improve quality of life3
- Connect with an Abbott Representative to learn more on how you can get started quickly and simply
Click below to access the CLEAR information of interest
The importance of
early detection
Access further information on PAD for yourself and your patients
Provide new innovations in PAD/CLTI treatment
In Their Own Words
Watch physicians and patients discuss the challenges of diagnosing PAD and the keys to effective care and treatment, from the importance of early detection to the goal of achieving better outcomes. All demonstrating how value-based care can transform the lives of people with CLTI and amputation prevention.
Series Trailer
Episode 1 - The Hidden Crisis: Why Traditional Approaches to Amputation Are Not Enough. Take a closer look at the real-world struggles faced by physicians and patients.
Episode 2 - Transforming Lives Through Amputation Prevention and Value-Based Care. Watch how a team of dedicated physicians makes a powerful impact on PAD and CLTI care, with the goal of optimizing patient outcomes.
Episode 3 - The Urgent Need for Amputation Prevention. Hear from a patient who faced the devastating prospect of life-altering amputation and the physician fighting to prevent it.
Patients diagnosed with peripheral artery disease (PAD) are likely to be concerned about their condition and will want to learn all they can about PAD and how it may affect them. PAD is a common disease affecting over 236 million people worldwide4 and presents in 15-20% of people >70 years of age.5
PAD is the presence of atherosclerotic arteries in the lower limbs, which leads to a reduction in blood flow to the extremities.6 PAD is associated with significant morbidity and mortality:
>10% of PAD patients undergo lower-extremity revascularization or amputation7
5-year mortality rate of 33%8
1 in 5 risk of MI, stroke, cardiovascular death, or hospitalization within one year7
Prevalence of PAD increases 2-fold every 10 years9
An early referral to treatment can make a difference
Early diagnosis and referral are key to avoiding long-term complications. Collaboration between referring physicians and vascular specialists is crucial to facilitating a smooth referral process and improving patient outcomes.10,11
Access further information on PAD for yourself and your patients
If you are a physician you can register to receive a toolkit with these materials and more:
- PAD management guidelines that provide the flow of PAD diagnosis and treatment according to current standard-of-care clinical guidelines
- A brochure to help your patients better understand PAD
- Patient-facing posters that highlight PAD risk factors and anatomy for your use in exam rooms
- A PAD risk checklist for your use with patients to assess PAD risk
- A simple guide for descriptions and instructions on how to use all the materials provided
Provide new innovations in PAD/CLTI treatment
The LIFE-BTK Study, published in the New England Journal of Medicine, is the first successful RCT to demonstrate superiority of investigational device over standard of care for treatment of BTK disease in CLTI patients.12 The 2-year data presented at VIVA 2024 demonstrated sustained efficacy and safety.13
Every Step Matters
Abbott’s comprehensive Peripheral product portfolio provides individualized solutions for every step of the process, from initial access to closure.
The information provided is not intended for medical diagnosis or treatment or as a substitute for professional medical advice.
Consult with a physician or qualified healthcare provider for appropriate medical advice.
This material is intended for use with healthcare professionals only.
References:
- Haigh KJ, et al. Vasc Med. 2013; 18(6): 325-30.
- Hirsch AT, et al. JAMA. 2001; 286(11): 1317-24.
- Wu A, et al. J Am Heart Assoc. 2017; 6(1): e004519.
- Song P, et al. Lancet Glob Health. 2019; 7(8): e1020-30.
- Norgren L, et al. J Vasc Surg. 2007; 45(1): S5-67.
- Peripheral Arterial Disease (PAD). CDC. Web. 27 Sep 2021.
- Steg G, et al. JAMA. 2007; 297(11): 1197-206.
- Tomson J, Lip GYH. BMC Cardiovasc Disord. 2005; 5: 15.
- Virani SS, et al. Circulation. 2021; 143(8): e254-743.
- Walker CM, et al. Clin Interv Aging. 2015: 10; 1147-53.
- Dhand S, et al. Semin Intervent Radiol. 2018; 35: 378-83.
- Varcoe, RL., et al. Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease. N Eng J Med. 2024;390:9-19.
- Brian G. DeRubertis et al., Two-Year Outcomes of the LIFE-BTK Randomized Controlled Trial Evaluating the Esprit™ BTK Drug-eluting Resorbable Scaffold for Treatment of Infrapopliteal Lesions, VIVA 2024.
MAT-2208563 v3.0
Stay Connected